Format

Send to

Choose Destination
Cost Eff Resour Alloc. 2018 Nov 9;16(Suppl 1):42. doi: 10.1186/s12962-018-0126-7. eCollection 2018.

Priority setting for the introduction of rotavirus vaccine: what evidence was essential?

Author information

1
Fogarty International Center, National Institutes of Health, 31 Center Drive, MSC 2220, Bethesda, MD 20892 USA.

Abstract

Rotavirus (RV) diarrhea is the most common cause of severe diarrhea in children worldwide and since 2006, vaccines have been available and recommended by WHO for use in all children. We developed protocols that countries could use to assess the burden of RV disease in their own countries and the cost-effectiveness of a program for vaccine introduction. A decade later and in the setting of extreme tiering of prices so that the poorest countries pay the least for the vaccine, more than 92 countries have introduced this vaccine into their national programs and more than 90 have not. Those countries that introduced determined by protocol that the burden of RV disease was substantial and the cost of vaccine reasonable, especially in low income settings where GAVI subsidizes the vaccines' purchase. However, elsewhere, WHO's global recommendation has not been enacted leaving a majority of the world's children still at risk of this severe and sometimes fatal disease. We remain with much to learn about how to encourage countries to make decisions that will improve the health of their own children.

KEYWORDS:

Childhood diarrhea; Rotavirus; Vaccine hesitancy; Vaccines

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center